By pursuing these research directions, we can continue to refine our approach to cardioprotection in trastuzumab therapy, ultimately improving the balance between effective cancer treatment and long-term cardiovascular health for patients undergoing HER2-targeted therapies. Here, ERBB2 is linked to cancer.